Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for... see more

Recent & Breaking News (NDAQ:XAIR)

Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GlobeNewswire July 24, 2023

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023

GlobeNewswire June 22, 2023

Beyond Air® Secures up to $40 Million Debt Financing

GlobeNewswire June 15, 2023

Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem

GlobeNewswire June 15, 2023

Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

GlobeNewswire May 16, 2023

Beyond Cancer(TM) Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting

GlobeNewswire April 19, 2023

Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer

GlobeNewswire March 23, 2023

Beyond Cancer(TM) to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting

GlobeNewswire March 14, 2023

Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023

GlobeNewswire February 22, 2023

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023

GlobeNewswire February 9, 2023

Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer

GlobeNewswire January 30, 2023

Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board

GlobeNewswire January 24, 2023

Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast

GlobeNewswire January 17, 2023

Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases

GlobeNewswire December 13, 2022

Beyond Air® To Participate in Piper's 34th Annual Healthcare Conference

GlobeNewswire November 17, 2022

Beyond Cancer(TM) Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

GlobeNewswire November 10, 2022

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023

GlobeNewswire November 8, 2022

Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

GlobeNewswire October 24, 2022

Beyond Air® Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

GlobeNewswire October 20, 2022

Beyond Air® Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) using the LungFit® GO at the CHEST Annual Meeting 2022

GlobeNewswire October 17, 2022